These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6336538)

  • 41. How important is the synclinal conformation of sulfonylureas to explain the inhibition of AHAS: a theoretical study.
    Jaña GA; Delgado EJ; Medina FE
    J Chem Inf Model; 2014 Mar; 54(3):926-32. PubMed ID: 24548139
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Search for Pharmacoepigenetic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment.
    Karaglani M; Ragia G; Panagopoulou M; Balgkouranidou I; Nena E; Kolios G; Papanas N; Manolopoulos VG; Chatzaki E
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):226-233. PubMed ID: 29396966
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extrapancreatic effects of sulfonylurea drugs.
    Kaku K; Inoue Y; Kaneko T
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S105-8. PubMed ID: 8529502
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Action of the sulfonylureas tolbutamide and glypentide on the lacticdehydrogenase plasma levels (author's transl)].
    García-Rafanell J; Morell-Mestre J
    Rev Esp Fisiol; 1974 Jun; 30(2):91-6. PubMed ID: 4421448
    [No Abstract]   [Full Text] [Related]  

  • 45. Antidiabetic sulfonylureas modulate farnesoid X receptor activation and target gene transcription.
    Steri R; Kara M; Proschak E; Steinhilber D; Schneider G; Schubert-Zsilavecz M
    Future Med Chem; 2010 Apr; 2(4):575-86. PubMed ID: 21426008
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients.
    Schotborgh CE; Wilde AA
    Cardiovasc Res; 1997 Apr; 34(1):73-80. PubMed ID: 9217875
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells.
    Kramer W; Müller G; Geisen K
    Horm Metab Res; 1996 Sep; 28(9):464-8. PubMed ID: 8911984
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lack of Ca2+ ionophoretic activity of hypoglycemic sulfonylureas in excitable cells and isolated secretory granules.
    Gylfe E; Hellman B
    Mol Pharmacol; 1982 Nov; 22(3):715-20. PubMed ID: 7155128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Current concepts of the pancreatic and extrapancreatic mechanisms of the action of peroral hypoglycemic sulfonylurea preparations].
    Poltorak VV; Gladkikh AI
    Probl Endokrinol (Mosk); 1985; 31(2):76-85. PubMed ID: 2859589
    [No Abstract]   [Full Text] [Related]  

  • 50. Hypoglycemic sulfonylureas: effect of structure on activity.
    McLAMORE WM; FANELLI GM; LAUBACH GD; P'AN SY
    Ann N Y Acad Sci; 1959 Mar; 74(3):443-8. PubMed ID: 13637582
    [No Abstract]   [Full Text] [Related]  

  • 51. ["First" and "second" generation sulfonylureas: distinction or difference? (author's transl)].
    Balant L
    Diabete Metab; 1978 Jun; 4(2):135-43. PubMed ID: 98364
    [No Abstract]   [Full Text] [Related]  

  • 52. Repaglinide and related hypoglycemic benzoic acid derivatives.
    Grell W; Hurnaus R; Griss G; Sauter R; Rupprecht E; Mark M; Luger P; Nar H; Wittneben H; Müller P
    J Med Chem; 1998 Dec; 41(26):5219-46. PubMed ID: 9857091
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical use of oral hypoglycemic agents.
    Hagg SA
    Am J Hosp Pharm; 1976 Sep; 33(9):943-7. PubMed ID: 790951
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride.
    Kramer W; Müller G; Girbig F; Gutjahr U; Kowalewski S; Hartz D; Summ HD
    Biochim Biophys Acta; 1994 May; 1191(2):278-90. PubMed ID: 8172913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Do sulfonylureas influence hepatic insulin clearance?
    Groop LC; Groop PH; Stenman S; Saloranta C; Tötterman KJ; Fyhrquist F; Melander A
    Diabetes Care; 1988 Sep; 11(8):689-90. PubMed ID: 3065007
    [No Abstract]   [Full Text] [Related]  

  • 56. Sulfonylureas and ischemic heart disease.
    Matz R
    Arch Intern Med; 1998 Feb; 158(4):411-2. PubMed ID: 9487240
    [No Abstract]   [Full Text] [Related]  

  • 57. [Biological properties of 1,2-benzisothiazole compounds. Hypoglycemic activity of some benzisothiazolylacylamidoethylbenzensulfonylureas].
    Amoretti L; Agosti A; Catellani PL
    Boll Soc Ital Biol Sper; 1971 May; 47(10):299-302. PubMed ID: 4999859
    [No Abstract]   [Full Text] [Related]  

  • 58. [Relationship between hypoglycemic activity and binding ability with bovine serum albumin of sulfonylurea related compounds (author's transl)].
    Yoshitomi H; Nakayama T; Goto S
    Yakugaku Zasshi; 1981 Oct; 101(10):926-31. PubMed ID: 7338790
    [No Abstract]   [Full Text] [Related]  

  • 59. Sulfonylureas: background and development of the field.
    Levine R
    Diabetes Care; 1984; 7 Suppl 1():3-7. PubMed ID: 6376027
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man.
    Pfeifer MA; Halter JB; Judzewitsch RG; Beard JC; Best JD; Ward WK; Porte D
    Diabetes Care; 1984; 7 Suppl 1():25-34. PubMed ID: 6376026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.